Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
Lee
Andrew G
AG
Newman
Nancy J
NJ
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced*; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010727:Phosphoric Diester Hydrolases; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration; D014786:Vision Disorders / Q000139:chemically induced
D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human